Moody Aldrich Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-852
Closed -$784K 200
2026
Q1
$784K Sell
852
-28
-3% -$28.4K 0.14% 120
2025
Q4
$946K Sell
880
-27
-3% -$25.8K 0.18% 118
2025
Q3
$692K Buy
907
+514
+131% +$382K 0.13% 119
2025
Q2
$306K Sell
393
-115
-23% -$89.4K 0.06% 143
2025
Q1
$420K Sell
508
-5
-1% -$4.16K 0.09% 125
2024
Q4
$396K Sell
513
-132
-20% -$109K 0.07% 140
2024
Q3
$571K Sell
645
-97
-13% -$87.2K 0.1% 121
2024
Q2
$672K Sell
742
-579
-44% -$463K 0.13% 118
2024
Q1
$1.03M Sell
1,321
-442
-25% -$315K 0.17% 120
2023
Q4
$1.03M Sell
1,763
-122
-6% -$71.2K 0.18% 115
2023
Q3
$1.03M Buy
+1,885
New +$971K 0.2% 116

Other funds holding LLY

Moody Aldrich Partners's LLY Position: Q2 2026 in Review

Moody Aldrich Partners sold out of Eli Lilly (LLY) in Q2 2026, closing a stake of 852 shares — an estimated $784K sold.

Moody Aldrich Partners first reported a position in LLY in Q3 2023 and held it in 11 quarters. The position peaked at $1.03M in Q3 2023. 1,842 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Moody Aldrich Partners reported no remaining Eli Lilly position as of Q2 2026 after selling out during the quarter.
  • Moody Aldrich Partners sold 852 Eli Lilly shares in Q2 2026, an estimated $784K.
  • Moody Aldrich Partners first reported a position in Eli Lilly in Q3 2023 and held it in 11 quarters.
  • Moody Aldrich Partners's Eli Lilly position peaked at $1.03M in Q3 2023.
  • 1,842 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.